Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NO2U is a line of dietary supplements developed by the company NO2U, primarily focused on enhancing systemic nitric oxide (NO) levels. The flagship product is an oral lozenge designed to support the nitrate-nitrite-nitric oxide pathway, which serves as an alternative route for NO production when the primary L-arginine pathway is impaired by age or endothelial dysfunction. These supplements are marketed to support cardiovascular health, promote vasodilation, and improve physical performance. The products are sold directly to consumers through e-commerce and are not classified as pharmaceutical drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NO2U.